首页> 中文期刊> 《糖尿病新世界 》 >黄芪益肾颗粒治疗临床期糖尿病肾病的临床可行性

黄芪益肾颗粒治疗临床期糖尿病肾病的临床可行性

             

摘要

Objective To study the choice astragalus kidney particles after treatment in patients with clinical stage of diabetic nephropathy have clinical effect. Methods Our hospital in 2013 June to 2015 June 106 patients with clinical stage of diabetic nephropathy. Through the draw method for randomized patients with diabetic nephropathy. B2 group (the control group (53 cases) choose the method of conventional drug treatment; B1 (observation group (53 cases) on the basis of B2 group choose astragalus treated kidney particles. Compare all the total effective rate in the treatment of diabetic nephropathy patients and fasting plasma glucose and other related indicators show the difference. Results All clinical stage of diabetic nephropathy after completion of treatment in the clinical total effective rate, B1 group is significantly higher than B2 diabetic nephropathy patients (P<0.05); In clinical indicators, B1 B2 is obviously better than the group of diabetic nephropathy patients (P<0.05). Conclusion According to the clinical stage of diabetic nephropathy patients, select the astragalus membranaceus kidney pellet treatment, can effectively exert the effect of yiqi Yin and invigorate the circulation of material supplement, will eventually improve on the quality of life of diabetic nephropathy patients.%目的:探讨选择黄芪益肾颗粒对临床期糖尿病肾病患者完成治疗后获得的临床效果。方法选择该院2013年6月—2015年6月临床期糖尿病肾病患者106例。通过抽签法对糖尿病肾病患者进行随机分组。B2组(对照组53例)选择常规药物治疗的方法;B1组(观察组53例)在B2组基础上选择黄芪益肾颗粒进行治疗。比较所有糖尿病肾病患者在治疗总有效率以及空腹血糖等相关指标方面表现出的差异。结果所有临床期糖尿病肾病患者完成治疗后,在临床治疗总有效率方面,B1组明显高于B2组糖尿病肾病患者(P<0.05);在临床指标方面,B1组明显优于B2组糖尿病肾病患者(P<0.05)。结论针对临床期糖尿病肾病患者,选择黄芪益肾颗粒进行治疗,能够有效发挥益气补阴以及活血降浊的效果,最终将糖尿病肾病患者的生活质量有效提高。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号